Contact
searchSearch
HMP Global
Login

Psych Congress Network

Latest News, Insights, and Quizzes

Mark Olfson, MD, MPH
Quiz
Telemental Health Use Patterns
01/16/2026
Maria Mantas
Are you caught up with the latest research on telehealth use patterns?
Are you caught up with the latest research on telehealth use patterns?
Are you caught up with the...
01/16/2026
Psych Congress Network
US FDA building
News
FDA Requests Removal of Suicide Risk Warnings From GLP-1 RA Labels
01/14/2026
Maria Mantas
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug...
01/14/2026
Psych Congress Network
illustration of a brain
News
Meta-Analysis Confirms Processing Speed as Core Cognitive Deficit in Schizophrenia
01/12/2026
Maria Mantas
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
Processing speed remains one of the most severely impaired cognitive domains in people with schizophrenia, according to a large systematic review and meta-analysis published in JAMA Psychiatry.
Processing speed remains one of...
01/12/2026
Psych Congress Network
FDA building
News
FDA Approves At-Home Neuromodulation Therapy Device for Major Depression
01/12/2026
Maria Mantas
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug...
01/12/2026
Psych Congress Network
woman on a hill
News
Delay Discounting Fails to Predict Antidepressant Relapse in MDD
01/09/2026
Maria Mantas
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests that while delay discounting is elevated in patients with remitted MDD, it neither changes after antidepressant medication discontinuation nor predicts subsequent depressive relapse.
A new multi-site study suggests...
01/09/2026
Psych Congress Network
Greg Mattingly, MD
Videos
VMAT-2 Inhibitor Differences and Dosing in Tardive Dyskinesia
01/09/2026
Greg Mattingly, MD
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg...
01/09/2026
Psych Congress Network
Steven Chan, MD, MBA
Videos
Digital Mental Health Trends: Policy, Telehealth, and Generative AI
01/07/2026
Steven Chan, MD, MBA
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress...
01/07/2026
Psych Congress Network
An illustration of a brain
News
Disease Duration, Antipsychotic Use, and Brain Aging in Schizophrenia
01/06/2026
Sarah Fleming
In a study published in Schizophrenia Research, investigators examined whether disease duration or antipsychotic exposure explains increases in brain age among patients with schizophrenia using MRI-based machine-learning models.
In a study published in Schizophrenia Research, investigators examined whether disease duration or antipsychotic exposure explains increases in brain age among patients with schizophrenia using MRI-based machine-learning models.
In a study published in...
01/06/2026
Psych Congress Network
Two pill bottles tipped over with pills on a table
News
Adolescent SSRI Use Not Causally Linked to Bipolar Disorder Risk, UK Registry Study Finds
01/06/2026
Sarah Fleming
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ Mental Health leveraged national United Kingdom (UK) health registry data to investigate whether selective serotonin reuptake inhibitor (SSRI) treatment in adolescents with unipolar depression influences later...
New research published in BMJ...
01/06/2026
Psych Congress Network
artificial intelligence
News
AI-Based Prediction Tool Flags Psychotic and Bipolar Disorder Risk
01/05/2026
Maria Mantas
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an artificial intelligence (AI)–enabled clinical prediction model may accurately identify individuals at risk of developing psychotic disorders or bipolar disorders.
A large UK study reports that an...
01/05/2026
Psych Congress Network
a group of clinicians
News
Collaborative Care Shows No Added Benefit for OUD With Depression or PTSD
01/02/2026
Maria Mantas
A collaborative care model tailored for low-resource primary care settings did not improve outcomes beyond enhanced usual care for adults with OUD and co-occurring depression and/or PTSD.
A collaborative care model tailored for low-resource primary care settings did not improve outcomes beyond enhanced usual care for adults with OUD and co-occurring depression and/or PTSD.
A collaborative care model...
01/02/2026
Psych Congress Network

Latest Expert Insights

Greg Mattingly, MD
Videos
VMAT-2 Inhibitor Differences and Dosing in Tardive Dyskinesia
01/09/2026
Greg Mattingly, MD
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg...
01/09/2026
Psych Congress Network
Greg Mattingly, MD
Videos
VMAT-2 Inhibitor Differences and Dosing in Tardive Dyskinesia
01/09/2026
Greg Mattingly, MD
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg...
01/09/2026
Psych Congress Network
Steven Chan, MD, MBA
Videos
Digital Mental Health Trends: Policy, Telehealth, and Generative AI
01/07/2026
Steven Chan, MD, MBA
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress...
01/07/2026
Psych Congress Network
Michael Asbach, DMsc, PA-C
Videos
Differentiating Bipolar II Disorder From Other Psychiatric Conditions
12/08/2025
Michael Asbach, DMSc, PA-C
In this video, Michael Asbach, DMSc, PA-C, walks clinicians through some key clinical considerations for navigating diagnostic ambiguity when assessing patients for bipolar II disorder.
In this video, Michael Asbach, DMSc, PA-C, walks clinicians through some key clinical considerations for navigating diagnostic ambiguity when assessing patients for bipolar II disorder.
In this video, Michael Asbach,...
12/08/2025
Psych Congress Network
Desiree Matthews, PMHNP-BC
Videos
Using Digital Tools to Reduce Clinician Burnout
12/03/2025
Desiree Matthews, PHMNP-BC
In this video filmed at Psych Congress 2025, Steering Committee member Desiree Matthews, PMHNP-BC, discusses the ways in which digital tools can be leveraged to reduce provider burnout.
In this video filmed at Psych Congress 2025, Steering Committee member Desiree Matthews, PMHNP-BC, discusses the ways in which digital tools can be leveraged to reduce provider burnout.
In this video filmed at Psych...
12/03/2025
Psych Congress Network
Craig Chepke, MD, DFAPA
Videos
Comparing Real-World Data on LAIs and Oral Antipsychotics
12/01/2025
Craig Chepke, MD, DFAPA
In this video, Craig Chepke, MD, DFAPA, discusses real-world findings that clinicians should be aware of when considering the use of oral or LAI antipsychotics for schizophrenia treatment.
In this video, Craig Chepke, MD, DFAPA, discusses real-world findings that clinicians should be aware of when considering the use of oral or LAI antipsychotics for schizophrenia treatment.
In this video, Craig Chepke, MD,...
12/01/2025
Psych Congress Network
Timothy Wilens, MD
Videos
Leveraging Digital Therapeutics for ADHD Management
11/14/2025
Timothy Wilens, MD
In this video filmed on-site at Psych Congress 2025, faculty member Timothy Wilens, MD, discusses the role that digital therapeutics may play in the management of attention-deficit/hyperactivity disorder (ADHD).
In this video filmed on-site at Psych Congress 2025, faculty member Timothy Wilens, MD, discusses the role that digital therapeutics may play in the management of attention-deficit/hyperactivity disorder (ADHD).
In this video filmed on-site at...
11/14/2025
Psych Congress Network
Jonathan Meyer, MD
Videos
Updated Approaches to Clozapine Monitoring Post-REMS
11/11/2025
Jonathan Meyer, MD
Filmed at the 2025 Psych Congress, Jonathan Meyer, MD, offers an updated approach for clinicians navigating clozapine monitoring following the end of Risk Evaluation and Mitigation Strategy (REMS) program.
Filmed at the 2025 Psych Congress, Jonathan Meyer, MD, offers an updated approach for clinicians navigating clozapine monitoring following the end of Risk Evaluation and Mitigation Strategy (REMS) program.
Filmed at the 2025 Psych...
11/11/2025
Psych Congress Network
Edward Kaftarian, MD
Videos
Avoiding Legal Gray Areas in Cross-State Telepsychiatry
11/04/2025
Edward Kaftarian, MD
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, dives into potential legal gray areas that clinicians may encounter when engaging in cross-state telepsychiatry.
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, dives into potential legal gray areas that clinicians may encounter when engaging in cross-state telepsychiatry.
In this video, Psych Congress...
11/04/2025
Psych Congress Network
Timothy Wilens, MD
Videos
Navigating Psychiatric Comorbidities in ADHD
10/17/2025
Timothy Wilens, MD
In this insightful discussion, Psych Congress Faculty Member Timothy Wilens, MD, dissects the challenges clinicians may face when diagnosing and treating common psychiatric comorbidities in individuals with ADHD.
In this insightful discussion, Psych Congress Faculty Member Timothy Wilens, MD, dissects the challenges clinicians may face when diagnosing and treating common psychiatric comorbidities in individuals with ADHD.
In this insightful discussion,...
10/17/2025
Psych Congress Network

From the Newsrooms

Steven Chan, MD, MBA
Videos
Digital Mental Health Trends: Policy, Telehealth, and Generative AI
01/07/2026
Steven Chan, MD, MBA
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress...
01/07/2026
Psych Congress Network
Timothy Wilens, MD
Videos
Leveraging Digital Therapeutics for ADHD Management
11/14/2025
Timothy Wilens, MD
In this video filmed on-site at Psych Congress 2025, faculty member Timothy Wilens, MD, discusses the role that digital therapeutics may play in the management of attention-deficit/hyperactivity disorder (ADHD).
In this video filmed on-site at Psych Congress 2025, faculty member Timothy Wilens, MD, discusses the role that digital therapeutics may play in the management of attention-deficit/hyperactivity disorder (ADHD).
In this video filmed on-site at...
11/14/2025
Psych Congress Network
Jonathan Meyer, MD
Videos
Updated Approaches to Clozapine Monitoring Post-REMS
11/11/2025
Jonathan Meyer, MD
Filmed at the 2025 Psych Congress, Jonathan Meyer, MD, offers an updated approach for clinicians navigating clozapine monitoring following the end of Risk Evaluation and Mitigation Strategy (REMS) program.
Filmed at the 2025 Psych Congress, Jonathan Meyer, MD, offers an updated approach for clinicians navigating clozapine monitoring following the end of Risk Evaluation and Mitigation Strategy (REMS) program.
Filmed at the 2025 Psych...
11/11/2025
Psych Congress Network
Edward Kaftarian, MD
Videos
Avoiding Legal Gray Areas in Cross-State Telepsychiatry
11/04/2025
Edward Kaftarian, MD
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, dives into potential legal gray areas that clinicians may encounter when engaging in cross-state telepsychiatry.
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, dives into potential legal gray areas that clinicians may encounter when engaging in cross-state telepsychiatry.
In this video, Psych Congress...
11/04/2025
Psych Congress Network
Craig Chepke, MD, DFAPA, Chief Medical Officer of Psych Congress
Press Release
Psych Congress Strengthens Clinical Leadership With Appointment of Craig Chepke, MD, DFAPA, as Chief Medical Officer
10/30/2025
Appointment reinforces HMP Global’s commitment to evidence-based, practice-ready mental health education that drives better patient outcomes.
Appointment reinforces HMP Global’s commitment to evidence-based, practice-ready mental health education that drives better patient outcomes.
Appointment reinforces HMP...
10/30/2025
Psych Congress Network
Julie Carbray, PhD, APRN, PMHNP-BC
Clinical Pearls
Addressing Side Effects: Advances in Bipolar Disorder Treatment
10/28/2025
Julie A. Carbray, PhD, APRN
Julie Carbray, PhD, PMHNP-BC, APRN, discusses how emerging therapies for bipolar disorder differ from traditional mood stabilizers, including improved tolerability and reduced side effects.
Julie Carbray, PhD, PMHNP-BC, APRN, discusses how emerging therapies for bipolar disorder differ from traditional mood stabilizers, including improved tolerability and reduced side effects.
Julie Carbray, PhD, PMHNP-BC,...
10/28/2025
Psych Congress NP Institute
attendees at the 2025 Psych Congress look at a research poster
Press Release
Psych Congress Honors Award Winners for Original Neuropsychiatric Research Posters at 2025 National Meeting
10/21/2025
HMP Global event recognizes five studies spanning major depressive disorder, schizophrenia, tardive dyskinesia, and post-traumatic stress disorder.
HMP Global event recognizes five studies spanning major depressive disorder, schizophrenia, tardive dyskinesia, and post-traumatic stress disorder.
HMP Global event recognizes five...
10/21/2025
Psych Congress Network
Julie Carbray, PhD, APRN, PMHNP-BC
APP Perspectives
How to Stay Updated on New Developments in Bipolar Disorder Treatment
10/21/2025
Julie A. Carbray, PhD, APRN
Julie Carbray, PhD, PMHNP-BC, APRN, shares practical strategies for staying up to date on evolving treatment options for bipolar disorder treatment.
Julie Carbray, PhD, PMHNP-BC, APRN, shares practical strategies for staying up to date on evolving treatment options for bipolar disorder treatment.
Julie Carbray, PhD, PMHNP-BC,...
10/21/2025
Psych Congress NP Institute
A patient sits across from a doctor who has a clipboard and is filling out a phone
Conference Coverage
Brexpiprazole/Sertraline Combo Shows Benefits for PTSD Symptoms
10/15/2025
Brionna Mendoza
In PTSD, brexpiprazole in combination with sertraline was associated with greater improvements in symptom severity and functioning compared to sertraline in combination with placebo across symptom clusters.
In PTSD, brexpiprazole in combination with sertraline was associated with greater improvements in symptom severity and functioning compared to sertraline in combination with placebo across symptom clusters.
In PTSD, brexpiprazole in...
10/15/2025
Psych Congress Network
Julie Carbray, PhD, APRN, PMHNP-BC
Clinical Pearls
Managing Cardiometabolic Adverse Effects in Bipolar Disorder
10/15/2025
Julie A. Carbray, PhD, APRN
Julie Carbray, PhD, PMHNP-BC, APRN, provides an overview of some of the key cardiometabolic symptoms and adverse effects that clinicians should be on the lookout for in their patients with bipolar disorder.
Julie Carbray, PhD, PMHNP-BC, APRN, provides an overview of some of the key cardiometabolic symptoms and adverse effects that clinicians should be on the lookout for in their patients with bipolar disorder.
Julie Carbray, PhD, PMHNP-BC,...
10/15/2025
Psych Congress NP Institute

Quizzes

Mark Olfson, MD, MPH
Quiz
Telemental Health Use Patterns
01/16/2026
Maria Mantas
Are you caught up with the latest research on telehealth use patterns?
Are you caught up with the latest research on telehealth use patterns?
Are you caught up with the...
01/16/2026
Psych Congress Network
illustration of a laptop screen displaying a test
Quiz
Stimulants and Psychosis Risk in ADHD
12/22/2025
Maria Mantas
Do you remember the findings from this systematic review?
Do you remember the findings from this systematic review?
Do you remember the findings...
12/22/2025
Psych Congress Network
Joseph Goldberg, MD
Quiz
Diagnosing Mixed Features in Bipolar Disorder
12/03/2025
Joseph F. Goldberg, MD
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
12/03/2025
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Depression, Inflammation, and Insomnia
11/19/2025
Brionna Mendoza
Test your knowledge with this quiz!
Test your knowledge with this quiz!
Test your knowledge with this...
11/19/2025
Psych Congress Network
quiz
Quiz
Early Lead Exposure and Mental Health Outcomes
11/10/2025
Maria Mantas
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
11/10/2025
Psych Congress Network
a teenager's hand putting a bag of white pills into another teenager's hand.
Quiz
Test Your Knowledge – Understanding Abuse Potential Across ADHD Therapies: What Clinicians Need to Know
10/23/2025
Curb misuse before it starts—test your diversion-prevention game in 3 quick questions.
Curb misuse before it starts—test your diversion-prevention game in 3 quick questions.
Curb misuse before it...
10/23/2025
Psych Congress Network
Edward Kaftarian, MD
Quiz
Building Patient Rapport in Telepsychiatry
10/09/2025
Edward Kaftarian, MD
Do you remember Dr Kaftarian's recommended strategies for building patient rapport via telehealth?
Do you remember Dr Kaftarian's recommended strategies for building patient rapport via telehealth?
Do you remember Dr Kaftarian's...
10/09/2025
Psych Congress Network
A woman sleeping peacefully
Quiz
Test Your Knowledge – ADHD and Sleep: Why Non-Stimulants Might Be the Right Choice (Part 3)
10/09/2025
Sleep and ADHD intersect—see if your management playbook is up to date in 3 quick questions.
Sleep and ADHD intersect—see if your management playbook is up to date in 3 quick questions.
Sleep and ADHD intersect—see if...
10/09/2025
Psych Congress Network
Blocks that spell ADHD with pills and a stethoscope
Quiz
Test Your Knowledge – The Rise of Non-Stimulant ADHD Treatments: A Paradigm Shift?
10/08/2025
Rethink ADHD beyond stimulants—test your non-stimulant savvy with 3 quick questions.
Rethink ADHD beyond stimulants—test your non-stimulant savvy with 3 quick questions.
Rethink ADHD beyond...
10/08/2025
Psych Congress Network
A boy sleeping peacefully.
Quiz
Test Your Knowledge – ADHD and Sleep: Why Non-Stimulants Might Be the Right Choice (Part 2)
09/29/2025
How well do you know the evidence on ADHD and sleep? Take this quick quiz to find out.
How well do you know the evidence on ADHD and sleep? Take this quick quiz to find out.
How well do you know the...
09/29/2025
Psych Congress Network

Recent FDA Updates

US FDA building
News
FDA Requests Removal of Suicide Risk Warnings From GLP-1 RA Labels
01/14/2026
Maria Mantas
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug...
01/14/2026
Psych Congress Network
FDA building
News
FDA Approves At-Home Neuromodulation Therapy Device for Major Depression
01/12/2026
Maria Mantas
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug...
01/12/2026
Psych Congress Network
FDA approval stamp
News
FDA Approves First At-Home tDCS Treatment for Major Depressive Disorder
12/16/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug...
12/16/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves Lumateperone Indication for Major Depressive Disorder
11/07/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug...
11/07/2025
Psych Congress Network
US FDA sign
News
FDA OKs Once Monthly Subcutaneous Risperidone for Bipolar I Disorder
10/20/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug...
10/20/2025
Psych Congress Network

Live Meetings

Psych Congress Family & Friends Podcast

Rakesh Jain and Craig Chepke
Podcasts
Psych Congress Family & Friends Podcast, Episode 8: Beyond the Headlines: The Good, The Bad, and The Ugly of SSRIs
10/09/2025
Public discussion often links psychiatric medications with violence, suicide, or even mass shootings—but what does the evidence actually say? In this episode, Drs. Rakesh Jain and Craig Chepke are joined by Dr. Ragy Girgis of Columbia...
Public discussion often links psychiatric medications with violence, suicide, or even mass shootings—but what does the evidence actually say? In this episode, Drs. Rakesh Jain and Craig Chepke are joined by Dr. Ragy Girgis of Columbia...
Public discussion often links...
10/09/2025
Psych Congress Network
Craig Chepke and Rakesh Jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 7: Sleep is the Foundation of Mental Health
09/12/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
Sleep–wake disorders are common, clinically significant, and too often overlooked in psychiatric practice. In this episode, Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating conditions such as insomnia,...
Sleep–wake disorders are common, clinically significant, and too often overlooked in psychiatric practice. In this episode, Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating conditions such as insomnia,...
Sleep–wake disorders are common,...
09/12/2025
Psych Congress Network
Rakesh Jain and Craig Chepke
Podcasts
Psych Congress Family & Friends Podcast, Episode 6: Psychiatry Is the Specialty That Speaks for Those Without a Voice
09/08/2025
Fibromyalgia is more than widespread pain—it’s a condition that blurs the lines between psychiatry, medicine, and the human experience. In this episode, Drs. Rakesh Jain and Craig Chepke discuss a newly approved treatment, explore why...
Fibromyalgia is more than widespread pain—it’s a condition that blurs the lines between psychiatry, medicine, and the human experience. In this episode, Drs. Rakesh Jain and Craig Chepke discuss a newly approved treatment, explore why...
Fibromyalgia is more than...
09/08/2025
Psych Congress Network
Craig Chepke and Rakesh Jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 5: We’re Too Addicted to Our Own Good Ideas
08/25/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain...
08/25/2025
Psych Congress Network
craig chepke and rakesh jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 4: Every Pill is a Choice
07/25/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
They are back! Through a positive psychiatry lens, Drs Rakesh Jain and Craig Chepke reflect on recent research, the challenges of psychiatric diagnosis, and why every treatment decision should begin with a deep understanding of the person in...
They are back! Through a positive psychiatry lens, Drs Rakesh Jain and Craig Chepke reflect on recent research, the challenges of psychiatric diagnosis, and why every treatment decision should begin with a deep understanding of the person in...
They are back! Through a...
07/25/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use